Restenosis is an important limitation of percutaneous coronary interventions (PCI). In-stent restenosis is mainly due to neointimal hyperplasia, a proliferative process modulated by inflammatory mechanisms. Numerous technical and pharmacological means have been tested to reduce restenosis rates, with frequently disappointing clinical results. Drug-eluting stents (DES) have demonstrated a high efficacy in reducing restenosis, but there are some associated problems that limit its generalized utilization. Glucocorticoids (GC), as potent anti-inflammatory agents, may exert beneficial effects on neointimal proliferation. Clinical studies with oral and intracoronary GC therapy have demonstrated reduction in restenosis rates in selected patients. Although further investigations are warranted, GC might have a potential role for restenosis prevention in selected cases.
Barnes, P.J. (2005) Molecular mechanisms and cellular effects of glucocorticosteroids . Immunol Allergy Clin North Am25: 451-468.
2.
Bavry, A.A., Chiu, J.H., Jefferson, B.K., Karha, J., Bhatt, D.L. and Ellis, S.G. (2007) Development of coronary aneurysm after drug-eluting stent implantation. Ann Intern Med146: 230-232.
3.
Buffon, A., Liuzzo, G., Biasucci, L.M., Pasqualetti, P., Ramazzotti, V., Rebuzzi, A.G. et al. (1999) Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty . J Am Coll Cardiol34: 1512-1521.
4.
Dibra, A., Mehili, J., Braun, S., Hadamitzky, M., Baum, H., Dirschinger, J. et al. (2005) Inflammatory response after intervention assesed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J150: 344-350.
5.
Douglas, J.S. (2007) Pharmacologic approaches to restenosis prevention . Am J Cardiol100: 10K-16K.
6.
Farb, A., Weber, D.K., Kolodgie, F.D., Burke, A.P. and Virmani, R. (2002) Morphological predictors of restenosis after coronary stenting in humans. Circulation105: 2974-2980.
7.
Ferrero, V., Ribichini, F., Pesarini, G., Brunelleschi, S. and Vassanelli, C. (2007a) Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential. Drugs67: 1243-1255.
8.
Ferrero, V., Ribichini, F., Rognoni, A., Marino, P., Brunelleschi, S. and Vassanelli, C. (2007b) Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study). Am J Cardiol99: 1082-1086.
9.
Finn, A.V., Nakazawa, G., Joner, M., Kolodgie, F.D., Mont, E.K., Gold, H.K. et al. (2007) Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol27: 1500-1510.
10.
Fukuda, D., Shimada, K., Tanaka, A., Kawarabayashi,T.,Yoshiyama, M. and Yoshikawa, J. (2004) Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol43: 18-23.
11.
Fuster, V., Moreno, P.R., Fayad, Z.A., Corti, R. and Badimon, J.J. (2005) Atherothrombosis and high risk plaque. Part I: Evolving concepts. J Am Coll Cardiol46: 937-954.
12.
Garas, S.M., Huber, P. and Scout, N.A. (2001) Overview of therapies for prevention of restenosis alter coronary interventions. Pharmacol Ther92: 165-178.
13.
Gaspardone, A. and Versaci, F. (2005) Coronary stenting and inflammation. Am J Cardiol96: 65L-70L.
14.
Gaspardone, A., Versaci, F., Tomai, F., Citone, C., Proietti, I., Gioffrè, G. et al. (2006) C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol97: 1311-1316.
15.
Grines, C.L., Bonow, R.O., Casey, D.E. Jr, Gardner, T.J., Lockhart, P.B., Moliterno, D.J. et al. (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol49: 734-739.
16.
Han, S.H., Ahn, T.H., Kang, W.C., Oh, K.J., Chung, W.J., Shin, M.S. et al. (2006) The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study. Am Heart J152: 887.e1-887.e7.
17.
Hara, H., Nakamura, M., Palmaz, J.C. and Schwartz, R.S. (2006) Role of stent design and coatings on restenosis and thrombosis. Adv Drug Deliv Rev58: 377-386.
18.
Hoffmann, R., Langenberg, R., Radke, P., Franke, A., Blindt, R., Ortlepp, J. et al. (2004) Evaluation of a high-dose dexamethasone-eluting stent. Am J Cardiol15;94: 193-195.
19.
Hojo,Y., Ikeda, U., Katsuki, T., Mizuno, O., Fukazawa, H., Kurosaki, K. et al. (2000) Interleukin 6 expression in coronary circulation after coronary angioplasty as risk factor for restenosis. Heart84: 83-87.
20.
Holmes Jr, D.R., Kereiakes, D.J., Laskey, W.K., Colombo, A., Ellis, S.G., Henry, T.D. et al. (2007) Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol50: 109-118.
21.
Huang, Y., Liu, X., Wang, L., Verbeken, E., Li, S. and De Scheerder, I. (2003) Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model . Int J Cardiovasc Intervent5: 166-171.
22.
Jaffe, R. and Strauss, B.H. (2007) Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol50: 119-127.
23.
Jimenez-Valero, S., Santos, B., Pajin, F., Canton, T., Lazaro, E., Moreu, J. et al. (2007) Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction. Catheter Cardiovasc Interv70: 492-497.
24.
Kastrati, A., Mehilli, J., Dirschinger, J., Dotzer, F., Schünlen, H., Neumann, F.J. et al. (2001) Intracoronary stenting and angiographic results. Strut thickness effect on restenosis outcome (ISAR-STEREO) Trial . Circulation103: 2816-2821.
25.
König, A., Leibig, M., Rieber, J., Schiele, T.M., Theisen, K., Siebert, U. et al. (2007) Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. Am Heart J153: 979.e1-8.
26.
Kuchulakanti, P. and Waksman, R. (2004) Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. Drugs64: 2379-2388.
27.
Lee, C.W., Chae, J.K., Lim, H.Y., Hong, M.K., Kim, J.J. and Park, S.W. (1999) Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J138: 60-63.
28.
Lew, R., Ajani, A. and Waksman, R. (2003) Review of intracoronary radiation for in-stent restenosis. J Invasive Cardiol SupplA: 2A-8A.
29.
Liu, X., Huang, Y., Hanet, C., Vandormael, M., Legrand, V., Dens, J. et al. (2003) Study of antirestenosis with the BiodivYsio Dexamethasone-eluting stent (STRIDE). Cath Cardiovasc Intervent60: 172-178.
30.
Liuzzo, G., Santamaria, M., Biasucci, L.M., Narducci, M., Colafrancesco, V., Porto, A. et al. (2007) Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein. J Am Coll Cardiol49: 185-194.
31.
Lowe, H.C., Oesterle, S.N. and Khachigian, L.M. (2002) Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol39: 183-193.
32.
Lucas, R.A., Korol, R. and Pepine, C.J. (2006) Inflammation in atherosclerosis. Some thoughts about acute coronary syndromes. Circulation113: e728-e732.
33.
McDonald, R.G., Panush, R.S. and Pepine, C.J. (1987) Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol60: 56B-60B.
34.
Menown, I., Lowe, R. and Penn, I. (2005) Passive stent coatings in the drug-eluting era . J Invasive Cardiol17: 222-228.
35.
Moreno, R. (2005) Drug-eluting stents and other anti-restenosis devices . Rev Esp Cardiol58: 842-862.
36.
Moreno, R., Fernandez, C., Sanchez-Recalde, A., Galeote, G., Calvo, L., Alfonso, F. et al. (2007) Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J28: 1583-1591.
37.
Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., Caputo, R.P. et al. (2003) Sirolimus-eluting stent versus standard stent in patients with stenosis in a native coronary artery. N Engl J Med349: 1315-1323.
38.
Mueller, C., Buettner, H.J., Hodgson, J.D., Marsch, S., Perruchoud, A.P., Roskamm, H. et al. (2006) Inflammation and long-term mortality after non ST-elevation acute coronary syndromes treated with a very early invasive strategy in 1042 consecutive patients. Circulation105: 1412-1415.
39.
Nebeker, J.R., Virmani, R., Bennett, C.L., Hoffman, J.M., Samore, M.H., Alvarez, J. et al. (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol47: 175-181.
40.
Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med356: 2457-2471.
41.
Ong, A.T., Daemen, J., Van Hoult, B.A., Lemos, P.A., Bosch, J.L., Van Domburg, R.T. et al. (2006) Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up . Results from the RESEARCH registry. Eur Heart J27: 2996-3003.
42.
Patti, G., Chello, M., Pasceri, V., Colonna, D., Carminati, P., Covino, E. et al. (2005a) Dexamethasone-eluting stents and plasma concentrations of adhesion molecules in patients with unstable coronary syndromes: results of the historically controlled SESAME study. Clin Ther27: 1411-1419.
43.
Patti, G., Pasceri, V., Carminati, P., D'Ambrosio, A., Carcagnì, A. and Di Sciascio, G. (2005b) Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol95: 502-505.
44.
Pepine, C.J., Hirshfeld, J.W., Macdonald, R.G., Henderson, M.A., Bass, T.A., Goldberg, S. et al. (1990) A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation81: 1753-1761.
45.
Rajagopal, V. and Rockson, S.G. (2003) coronary restenosis: a review of mechanisms and management. Am J Med115: 547-553.
46.
Rhen,T. and Cidlowski, J.A. (2005) Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med353: 1711-1723.
47.
Ribichini, F., Tomai, F., Ferrero, V.Versaci, F., Bocuzzi, G., Proietti, I. et al. (2005) Immunosuppressive oral prednisone alter percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS 2/MVD study. Eurointerv1: 173-180.
48.
Ribichini, F., Joner, M., Ferrero, V., Finn, A.V., Crimins, J., Nakazawa, G. et al. (2007a) Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol50: 176-185.
49.
Ribichini, F., Ferrero, V., Rognoni, A., Marino, P., Brunelleschi, S. and Vassanelli, C. (2007b) Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study. J Interv Cardiol20: 114-121.
50.
Ribichini, F., Ferrero, V., Feola, M., Rognoni, A., Brunelleschi, S., Vacca., G. et al. (2007c) Neutropenia in patients treated with thienopiridines and high-dose oral prednisone after percutaneous coronary interventions. J Interv Cardiol20: 209-213.
51.
Ribichini, F., Tomai, F., Paloscia, L., Di Sciascio, G., Carosio, G., Romano, M. et al. (2007d) Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry . Heart93: 598-600.
52.
Rittersma, S., de Winter, R.J., Koch, K., Bax, M., Schotborgh, C.E., Mulder, K.J. et al. (2004) Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol93: 477-480.
53.
Rodriguez, A.E., Granada, J.F., Rodriguez-Alemparte, M.„ Vigo, C.F., Delgado, J., Fernandez-Pereira, C. et al. (2006) Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol47: 1522-1529.
54.
Rosmarakis, E.S. and Falagas, M.E. (2007) Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J154: 144-150.
55.
Ross, R. (1999) Atherosclerosis: an inflammatory disease. N Engl J Med340: 115-126.
56.
Saleh, N. and Tornvall, P. (2007) Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis195: 374-378.
57.
Stone, G.W., Ellis, S.G., Cox, D.A., Hermiller, J., O'Shaughnessy, C., Mann, J.T. et al. (2004) A polymer based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med350: 221-231.
58.
Toutouzas, K., Colombo, A. and Stefanadis, C. (2004) Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J25: 1679-1687.
59.
Versaci, F., Gaspardone, A., Tomai, F., Ribichini, F., Russo, P., Proietti, I. et al. (2002) Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol40: 1935-1942.
60.
Waksman, R., Ajani, A.E., Pichard, A.D., Torguson, R., Pinnow, E., Canos, D. et al. (2004) Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol44: 1386-1392.
Wang, L., Salu, K., Verbeken, E., Bosmans, J., Van de Werf, F. and De Scheerder, I.(2005) Stent-mediated methylprednisolone delivery reduces macrophage contents and in-stent neointimal formation. Coron Artery Dis16: 237-243.
63.
Weintraub, W.S. (2007) The pathophysiology and burden of restenosis. Am J Cardiol100[suppl]: 3K-9K.
64.
Welt, F.G. and Rogers, C. (2002) Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol22: 1769-1776.
65.
Wijns, W. (2005) Blowing against the wind? Eurointervention1: 127-127.
